1   2  
Antiproliferative effects of novel synthetic nucleobase analogues on U937 Histiocytic lymphoma cell line
Alessandro, Trentini; Eugenia, Sapienza; Arianna, Romani; Maria Cristina Manfrinato, ; Tiziana, Bellini; Barbara, Cacciari; Stefania, Hanau     dettagli >>
EdiSES, SIB 2017 – 59th Congress – Italian Society of Biochemistry and Molecular Biology Book of Abstract
pp: 117-118, Anno: 2017

Dopamine conjugation with A2A Antagonist: enhancement of drug effect and its controlled release in brain homogenates
A. Dalpiaz; B. Cacciari; C.B. Vicentini; F. Bortolotti; G. Spalluto; S. Federico; B. Pavan; F. Vincenzi; P.A. Borea; K. Varani     dettagli >>
Università degli Studi di Firenze, XXII Simposio ADRITELF, 40 anni di Tecnologia Farmaceutica
pp: 82-82, Anno: 2012

Conjugation of Dopamine and an A2A Adenosine Receptor Antagonist: a possible approach for the treatment of Parkinson’s Disease.
A. Dalpiaz; B. Cacciari; C. B. Vicentini; F. Bortolotti; G. Spalluto; S. Federico; B. Pavan; F. Vincenzi; P. A. Borea; K. Varani.     dettagli >>
European Federation for Medicinal Chemistry; Università degli Studi di Palermo, 21ST NATIONAL MEETING ON MEDICINAL CHEMISTRY
pp: 144-144, Anno: 2012

Solid lipid microparticles for the stability enhancement of a dopamine prodrug
A. Dalpiaz; B. Cacciari; M. Mezzena; M. Strada; S. Scalia     dettagli >>
Associazione Docenti Ricercatori Italiani di Tecnologie e Legislazione Farmaceutiche, XXI Simposio A.D.R.I.T.E.L.F. Programma & Abstracts
pp: 124-124, Anno: 2009

5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists.
Pastorin G.; Da Ros T.; Bolcato C.; Montopoli C.; Moro S.; Cacciari B.; Baraldi P.G.; Varani K.; Borea P.A.; Spalluto G.    
PURINERGIC SIGNALLING
Vol. 2, No. 1, pp: 79-79, Anno: 2006

Synthesis, biological and modeling studies of new water soluble hA3 adenosine receptor antagonists.
Pastorin G.; Da Ros T.; Bolcato C.; Montopoli C.; Moro S.; Cacciari B.; Baraldi P.G.; Varani K.; Borea P.A.; Spalluto G.    
-, -
pp: 53-53, Anno: 2005

Triazolo-triazine as new adenosine receptor antagonists.
Pastorin G.; Da Ros T.; Spalluto G.; Jacobson KA.; Cacciari B.; Varani K.; Moro S.; Klotz KN.; Borea PA.    
-, -
pp: ---, Anno: 2003

Rationale design of new human adenosione A3 receptor antagonists through a CoMFA model.
Braiuca P.; Bonutti C.; Pastorin G.; Da Ros T.; Spalluto G.; Jacobson KA.; Cacciari B.; Moro S.; De Florian F.; Varani K.; Borea PA.    
-, -
pp: ---, Anno: 2003

Recent developments in the field of adenosine receptor ligands.
Baraldi P.G.; Fruttarolo F.; Tabrizi M.A.; Cacciari B.; Spalluto G.; Romagnoli R.; Pavani M.G.; Nuez Carretero M.C.; Varani K.; Borea P.A.    
-, -
pp: ---, Anno: 2002

Synthesis, biological properties and molecular modelling investigation of the first potent, selective and water soluble human A3 adenosine receptor antagonist.
Maconi A.; Pastorin G.; Da Ros T.; Spalluto G.; Gao Z.G.; Jacobson K.A.; Baraldi P.G.; Cacciari B.; Varani K.; Moro S.; Borea P.A.    
-, -
pp: ---, Anno: 2002

New potent and selective human adenosine A3 receptor antagonists.
Varani K.; Gessi S.; Merighi S.; Iannotta V.; Leung E.; Klotz K.N.; Baraldi P.G.; Cacciari B.; Romagnoli R.; Spalluto G.; Borea P.A.    
PHARMACOLOGICAL RESEARCH
Vol. 43, No. 1, pp: 17-17, Anno: 2001

Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists.
Baraldi P.G.; Cacciari B.; Moro S.; Romagnoli R.; Gessi S.; Pastorin G.; De Ros T.; Varani K.; Borea P.A.; Spalluto G.    
-, -
pp: ---, Anno: 2001

Pyrazolo[4,3-e]1,2,4-triazolo[1,5]pyrimidine derivates as irreversible antagonists at the human A3 adenosine receptor
Baraldi P.G.; Cacciari B.; Moro S.; Romagnoli R.; Xiao-duo J.; Jacobson K.; Gessi S.; Varani K.; Borea P.A.; Spalluto G.    
International Union of Pure and Applied Chemistry, -
pp: ---, Anno: 2001

7-sobstituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonist: importance of modifications at the side chain on the activity and solubility.
Baraldi P.G.; Cacciari B.; Romagnoli R.; Spalluto G.; Monopoli A.; Ongini E.; Varani K.; Borea P.A.    
-, -
pp: ---, Anno: 2001

7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility.
Cacciari B.; Baraldi P.G.; Romagnoli P.G.; Spalluto G.; Monopoli A.; Ongini E.; Varani K.; Borea P.A.    
-, -
pp: ---, Anno: 2001

New potent and selective human adenosine A3 receptor antagonists
K. Varani; S. Gessi; S. Merighi; V. Iannotta; E. Leung; K.N. Klotz; P.G. Baraldi; B. Cacciari; R. Romagnoli; G. Spalluto; P.A. Borea    
Società Italiana di Farmacologia, -
Vol. -, No. 1, pp: ---, Anno: 2001

Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4,-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists.
Cacciari B.; Moro S.; Romagnoli R.; Baraldi P.G.; Gessi S.; Pastorin G.; Da Ros T.; Varani K.; Borea P.A.; Spalluto G.    
-, -
pp: ---, Anno: 2001

Pyrazolo [4,3-E]1,2,4-triazolo[1,5-c]pyrimidine derivates a new class of potent and selective human A3 adenosine receptor antagonists.
Baraldi P.G.; Cacciari B.; Romagnoli R.; Spalluto G.; Klotz K.N.; Leung E.; Varani K.; Merighi S.; Gessi S.; Borea P.A.    
DRUG DEVELOPMENT RESEARCH
Vol. 50, No. 1, pp: 6-6, Anno: 2000

Synthesis and pharmacological characterization of [3H]-MRE3008F20: the first radioligand antagonist for the human A3 adenosine receptors.
Varani K.; Baraldi P.G.; Cacciari B.; Romagnoli R.; Gessi S.; Merighi S.; Borea P.A.; Leung E.; Spalluto G.    
-, -
pp: ---, Anno: 2000

Pyrazolo-triazolo-pyrimidine derivates as adenosine receptor ligands: a search for A2B adenosine receptor antagonists.
Cacciari B.; Spalluto G.; Baraldi P.G.; Romagnoli R.; Varani K.; Gessi S.; Merighi S.; Borea P.A.    
-, -
pp: ---, Anno: 2000

1   2